Search the Newsreel

Immunovant CFO Tiago Girao sells $263,014 in company stock

Immunovant's CFO, Tiago Girao, sold 6,798 shares of company stock for approximately $263,014, a transaction primarily to cover tax withholding obligations on restricted stock units. This "sell to cover" action was mandated by company policy and not a discretionary sale. The sale occurred while …

Immunovant director Atul Pande sells $59,699 in shares

Immunovant director Atul Pande sold 1,500 shares of the company's common stock for $59,699 on July 24, 2026, as part of a Rule 10b5-1 Plan. The sale occurred after he exercised stock options for the same number of shares at a lower price. Following …

Immunovant (NASDAQ: IMVT) CFO sells 6,798 shares to cover RSU taxes

Immunovant, Inc.'s CFO, Tiago Girao, sold 6,798 shares of common stock at a weighted average price of $38.69 per share on July 23, 2026. This transaction was a "sell to cover" to fund tax withholding obligations for 13,024 vested Restricted Stock Units (RSUs), leaving …

Immunovant CTO Jay Stout Executes Share Sale to Meet Tax Obligations Post-RSU Vesting

Immunovant's Chief Technology Officer, Jay Stout, sold company shares to fulfill tax obligations after his restricted stock units vested. This transaction offers insights for investors into the company's compensation and tax management strategies. The full article content is behind a login wall.

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Immunovant, Inc. (Nasdaq: IMVT) announced it will release its financial results for the first quarter ended June 30, 2026, on Thursday, August 6, 2026, before the market opens. Following this, Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant’s majority stockholder, will host a live conference call …

Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed

Immunovant, Inc.'s CEO, Eric Venker, is estimated to have received $20,158,767 in compensation in 2026 based on a recent SEC filing. Insider trading activity for IMVT stock over the last 6 months shows 36 sales and zero purchases. Additionally, recent hedge fund activity indicates …

Immunovant, Inc. SEC Filing (Jul 22, 2026)

This article reports on an ARS SEC filing by Immunovant, Inc. (IMVT) on July 22, 2026. The filing has a low impact and neutral sentiment according to AI analysis. The article also provides a summary of IMVT's stock overview, recent news, and other SEC …

Immunovant stock trades steady as cash reserves support ongoing autoimmune drug trials

Immunovant Inc. (IMVT) stock is stable due to significant cash reserves, which are funding ongoing clinical trials for its lead autoimmune drug, batoclimab. Despite minimal revenue and widening operating losses from high R&D spending, the company's substantial cash balance is expected to cover multiple …

Law firm investigates Immunovant officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating whether officers and directors of Immunovant, Inc. violated their fiduciary duties through potential self-dealing. This probe could result in damages for shareholders and corporate governance reforms, prompting long-term Immunovant investors to seek legal consultation. The investigation highlights concerns regarding …

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to …

Understanding Momentum Shifts in (IMVT)

Immunovant Inc. (NASDAQ: IMVT) is showing neutral near and mid-term readings, potentially moderating a long-term positive bias. No clear price positioning or resistance levels above the current price suggest compelling upside potential. The article provides institutional trading strategies for various risk profiles, including position …

IMVT Q2 2026 Earnings: Wider-than-Expected Loss as Immunovant Advances Batoclimab Pipeline - Earnings Revision Downgrade

Immunovant (IMVT) Stock Could Be 14.1% Undervalued After Loss And Trial Updates

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?

Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

Immunovant Stock Surges Despite Disappointing Earnings Miss - Immunovant (NASDAQ:IMVT)

Immunovant Shares Rally on Positive Trial Results Despite Earnings Miss (IMVT)

Crude Oil Down 5%; Lowe's Posts Upbeat Earnings - Immunovant (NASDAQ:IMVT), Lowe's Companies (NYSE:LOW)

IMMUNOVANT ($IMVT) Releases Q4 2026 Earnings

SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX

Immunovant Q4 Earnings Call Highlights

IMVT Stock Falls Pre-Market After Trial Miss, Days After Viridian’s Mixed Win

Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update

Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones